학술논문
Real-world use of remdesivir for the treatment of patients admitted to Italian hospitals with COVID-19: the nationwide retrospective DOI-RECOVER study.
Document Type
Article
Author
Pieralli, Filippo; Pomero, Fulvio; Dentali, Francesco; Norbiato, Claudio; Attardo, Tiziana; Vicari, Susanna; Magnani, Elena; Marzilli, Maria Antonietta; Piccolo, Paola; Valerio, Antonella; Manfellotto, Dario; Brugiotti, Elena; Carella, Vincenzo; Coppo, Martina; Ferrando, Francesca; Lauritano, Marta.; Marchetti, Bruno; Vitale, Francesco; Gasperina, Daniela Dalla; Baroni, Elena
Source
Subject
*REMDESIVIR
*DRUG side effects
*COVID-19
*ARTIFICIAL respiration
*COVID-19 treatment
*COMORBIDITY
*
*
*
*
*
Language
ISSN
1471-2334
Abstract
Background: Remdesivir is widely used for treatment of SARS-CoV-2 pneumonia. The aim of this study was to evaluate the characteristics of patients with moderate-to-severe COVID-19 treated with remdesivir, and their outcomes during hospitalization. Methods: This retrospective observational multicenter study included consecutive patients, hospitalized for moderate-to-severe COVID-19 (September 2020—September 2021), who were treated with remdesivir. Results: One thousand four patients were enrolled, all with onset of symptoms occurring less than 10 days before starting remdesivir; 17% of patients had 4 or more concomitant diseases. Remdesivir was well tolerated, adverse drug reactions (ADRs) being reported in 2.3% of patients. In-hospital death occurred in 80 patients (8.0%). The median timing of the first remdesivir dose was 5 days after symptom onset. The following endpoints did not differ according to the time span from the onset of symptoms to the first dose: length of hospitalization, in-hospital death, composite outcome (in-hospital death and/or endotracheal intubation). Advanced age, number of comorbidities ≥ 4, and severity of respiratory failure at admission were associated with poor in-hospital outcomes. Conclusion: In a real-world setting, remdesivir proved to be a safe and well-tolerated treatment for moderate-to-severe COVID-19. In patients receiving remdesivir less than 3 or 5 days from the onset of SARS-CoV-2 symptoms, mortality and the need for mechanical ventilation did not differ from the rest of the sample. [ABSTRACT FROM AUTHOR]